FDA raises doubts about trial of Sarepta lead drug, shares plunge

FDA raises doubts about trial of Sarepta lead drug, shares plunge

(Reuters) – Sarepta Therapeutics Inc said the U.S. Food and Drug Administration has expressed doubts that the design and goals for the trial of its lead drug were sufficient to support marketing approval, sending its shares down nearly 60 percent. The

3
Like
Save

Comments

Write a comment

*